North America Urinary Tract Infection Testing Market (By Type: Urethritis, Cystitis, Pyelonephritis; By Product; By End-use: Reference Laboratories, General Practitioners) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The North America urinary tract infection testing market was surpassed at USD 204.58 million in 2023 and is expected to hit around USD 304 million by 2033, growing at a CAGR of 4.04% from 2024 to 2033.

Key Pointers

• The cystitis segment accounted for the largest revenue share of 43% in 2023.
• The instruments segment accounted for the largest revenue share of 62% in 2023.
• The reference laboratories segment held the largest revenue share of 28% in 2023.

North America Urinary Tract Infection Testing Market Overview

Urinary tract infections (UTIs) represent a significant healthcare concern in North America, affecting millions of individuals annually. As such, the urinary tract infection testing market in the region plays a crucial role in diagnosis, management, and prevention strategies. This overview aims to provide insights into the key factors shaping the UTI testing market landscape in North America.

North America Urinary Tract Infection Testing Market Growth Factors

The growth of the North America urinary tract infection (UTI) testing market is driven by an increasing prevalence of UTIs in the region is a significant driver, prompting higher demand for diagnostic solutions. Additionally, rising awareness among both healthcare professionals and patients about the importance of early detection and treatment of UTIs is driving market growth. Technological advancements in diagnostic testing methods, such as the development of rapid point-of-care tests and molecular diagnostics, are also contributing to the market's expansion. Furthermore, initiatives aimed at promoting preventive healthcare and reducing healthcare-associated infections are bolstering market demand. Overall, these growth factors underscore the importance of UTI testing in North America's healthcare landscape and its potential for further expansion in the coming years.

Report Scope of the North America Urinary Tract Infection Testing Market

North America Urinary Tract Infection Testing Market Trends:

• Adoption of Automated Testing Platforms: There is a noticeable trend towards the adoption of automated testing platforms in North America, driven by the need for efficiency and accuracy in UTI diagnosis. These platforms streamline the testing process, reduce turnaround times, and improve workflow efficiency in clinical laboratories.
• Demand for Non-Invasive Testing Methods: Patients and healthcare providers alike are increasingly seeking non-invasive UTI testing methods. This trend is fueled by the growing preference for patient comfort and convenience, as well as the desire to minimize the risk of infection transmission. Non-invasive testing methods such as urine dipstick tests and molecular diagnostics are gaining traction in the market.
• Integration of Artificial Intelligence (AI) and Machine Learning (ML): The integration of AI and ML algorithms into UTI testing platforms is becoming more prevalent in North America. These technologies enable more accurate interpretation of test results, enhance diagnostic capabilities, and support personalized treatment approaches. By analyzing large datasets, AI and ML algorithms can identify patterns and correlations that may not be apparent to human observers, thereby improving diagnostic accuracy and clinical decision-making.
• Emphasis on Remote Monitoring and Telehealth Solutions: The COVID-19 pandemic has accelerated the adoption of remote monitoring and telehealth solutions for UTI testing in North America. Telehealth platforms enable patients to consult with healthcare providers remotely, facilitating timely diagnosis and treatment of UTIs without the need for in-person visits. Additionally, remote monitoring solutions allow for continuous tracking of patient health metrics, enabling early detection of UTI recurrence or complications.

Type Insights

The cystitis segment accounted for the largest revenue share of 43% in 2023 in the North America urinary tract infection testing market. Cystitis is a condition where bacteria from the skin or bowel enter the urethra and bladder, leading to irritation and inflammation of the bladder lining, causing a bladder infection. There are two types of cystitis - acute, which occurs suddenly; and interstitial, a chronic and longer-term condition. The growth of the segment is due to the rising incidence & recurrence rate of cystitis, the increased number of product approvals, and the high number of diabetes patients more prone to cystitis.

The pyelonephritis segment is expected to witness the fastest CAGR over the forecast period. This is owing to the increasing cases of pyelonephritis in the region. According to NCBI statistics, each year, there are approximately 250,000 cases of pyelonephritis in the U.S., with a higher occurrence among females. Among women aged between 18 to 49 years, the estimated incidence of pyelonephritis is 28 cases per 10,000 individuals, and around 7% of these cases require hospital admission. Recurrence is less frequent than uncomplicated UTIs, with 9% of females and 5.7% of males experiencing a second episode within a year.

Product Insights

The instruments segment accounted for the largest revenue share of 62% in 2023 and is expected to witness the fastest CAGR over the forecast period. The rising prevalence of UTIs in North America has led to a greater demand for efficient and reliable testing methods. Instruments are crucial in UTI testing as they are essential for accurate and rapid diagnosis. Advanced diagnostic instruments, such as automated urine analyzers and point-of-care testing devices, have gained traction due to their ability to deliver faster and more precise results. These instruments aid in detecting UTIs early, allowing for prompt treatment and improved patient outcomes.

Additionally, ongoing advancements in diagnostic technologies have led to the development of sophisticated instruments with enhanced capabilities. For instance, the increasing adoption of innovative UTI testing instruments, such as the Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP), is revolutionizing the UTI testing market in the region. These advanced instruments offer greater accuracy and sensitivity, attracting healthcare providers and driving market growth.

End-use Insights

The reference laboratories segment held the largest revenue share of 28% in 2023. Reference laboratories offer a wide range of comprehensive testing services, including UTI testing, to healthcare providers. These laboratories have advanced instruments and technologies to perform various diagnostic tests with high accuracy and efficiency. Moreover, many reference laboratories have multiple locations and wide geographic coverage, enabling them to serve a large population across different states and regions in North America. In addition, reference labs can handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices, which is anticipated to offer economies of scale to service providers.

The urogynecologists segment is expected to witness the fastest CAGR over the forecast period. Urogynecologists primarily focus on women's health concerns, including conditions that affect the urinary tract. Since UTIs are more prevalent in women, urogynecologists encounter and manage UTI cases more frequently than other healthcare specialists. They also perform specific tests to identify the underlying cause of recurrent UTIs and recommend appropriate treatment plans. This comprehensive approach to UTI diagnosis and management may contribute to the growth of UTI testing services within the urogynecology segment.

North America Urinary Tract Infection Testing Market Key Companies

• QIAGEN
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• bioMérieux SA
• T2 Biosystems, Inc.

North America Urinary Tract Infection Testing Market Segmentations:

By Type 

• Urethritis
• Cystitis
• Pyelonephritis

By Product 

• Instruments
• Consumables

By End-use 

• General practitioners
• Urologists
• Urogynecologists
• Hospital Laboratories
• Reference Laboratories
• Hospital Emergency Departments
• Urgent Care
• Others